CL2008001984A1 - Formulacion de anticuerpo anti-cd20; y su uso para tratar enfermedades que implican celulas que expresan cd20 en un mamifero. - Google Patents
Formulacion de anticuerpo anti-cd20; y su uso para tratar enfermedades que implican celulas que expresan cd20 en un mamifero.Info
- Publication number
- CL2008001984A1 CL2008001984A1 CL2008001984A CL2008001984A CL2008001984A1 CL 2008001984 A1 CL2008001984 A1 CL 2008001984A1 CL 2008001984 A CL2008001984 A CL 2008001984A CL 2008001984 A CL2008001984 A CL 2008001984A CL 2008001984 A1 CL2008001984 A1 CL 2008001984A1
- Authority
- CL
- Chile
- Prior art keywords
- mammal
- expressing cells
- treat diseases
- diseases involving
- antibody formulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
ESTA INVENCIÓN SE REFIERE A FORMULACIONES DE ANTICUERPO ANTI-CD20/ANTÍGENO DE DIFERENCIACIÓN RESTRINGIDO A LOS LINFOCITOS BIBP35, QUE COMPRENDE UN ANTICUERPO ANTI-CD20, EN LA QUE LA FORMULACIÓN COMPRENDE ADEMÁS ACETATO SÓDICO 10 A 100 MM, CLORURO SÓDICO 25 A 100 MM, ARGININA AL 0,5 A 5% P/V, EDTA 0,02 A 0,2 MM, POLISORBATO 80 AL 0,01 A 0,2% P/V Y ESTÁ AJUSTADA A PH 5,0 A 7,0. ADEMÁS DEL USO DE DICHAS FORMULACIONES QUE SIRVEN PARA PREPARAR UN MEDICAMENTO ÚTIL PARA TRATAR UNA ENFERMEDAD QUE IMPLICA CÉLULAS QUE EXPRESAN CD20 EN UN MAMÍFERO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94822007P | 2007-07-06 | 2007-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008001984A1 true CL2008001984A1 (es) | 2009-01-09 |
Family
ID=40228991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2008001984A CL2008001984A1 (es) | 2007-07-06 | 2008-07-04 | Formulacion de anticuerpo anti-cd20; y su uso para tratar enfermedades que implican celulas que expresan cd20 en un mamifero. |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US20110020328A1 (es) |
| EP (2) | EP2889310B1 (es) |
| JP (1) | JP5529017B2 (es) |
| KR (2) | KR101670454B1 (es) |
| CN (1) | CN101820912B (es) |
| AR (2) | AR067455A1 (es) |
| AU (1) | AU2008275278B2 (es) |
| BR (2) | BRPI0814003B1 (es) |
| CA (1) | CA2692681C (es) |
| CL (1) | CL2008001984A1 (es) |
| CO (1) | CO6270340A2 (es) |
| CR (1) | CR11249A (es) |
| CY (3) | CY1118419T1 (es) |
| DK (2) | DK2889310T3 (es) |
| DO (1) | DOP2010000001A (es) |
| EA (1) | EA017994B1 (es) |
| ES (2) | ES2610821T3 (es) |
| FR (1) | FR21C1040I1 (es) |
| HR (2) | HRP20170033T1 (es) |
| HU (3) | HUE038501T2 (es) |
| IL (1) | IL202950A (es) |
| JO (1) | JO3219B1 (es) |
| LT (3) | LT2170388T (es) |
| MA (1) | MA31471B1 (es) |
| MX (1) | MX2010000017A (es) |
| MY (1) | MY210424A (es) |
| NO (2) | NO2889310T3 (es) |
| NZ (1) | NZ582250A (es) |
| PE (1) | PE20090738A1 (es) |
| PL (2) | PL2889310T3 (es) |
| PT (2) | PT2170388T (es) |
| SI (2) | SI2170388T1 (es) |
| TR (1) | TR201802928T4 (es) |
| TW (2) | TWI612060B (es) |
| UA (1) | UA107557C2 (es) |
| UY (1) | UY31210A1 (es) |
| WO (1) | WO2009009407A1 (es) |
| ZA (1) | ZA200909107B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| EP2173163A4 (en) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
| EP3409289B1 (en) | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| RS59830B1 (sr) | 2010-03-01 | 2020-02-28 | Bayer Healthcare Llc | Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi) |
| RU2012153786A (ru) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
| SG193964A1 (en) * | 2011-04-07 | 2013-11-29 | Glaxosmithkline Llc | Formulations with reduced viscosity |
| TWI907924B (zh) * | 2011-05-02 | 2025-12-11 | 日商武田藥品工業股份有限公司 | 抗-α4β7抗體之調配物 |
| AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| CN105611909B (zh) * | 2013-03-12 | 2020-09-15 | 普莱玛疗法公司 | 包含螯合剂和碱的牙用组合物 |
| EP2805730A1 (en) * | 2013-05-21 | 2014-11-26 | Bergen Teknologioverforing AS | Nitric oxide donor for the treatment of chronic fatigue syndrome |
| WO2015162504A1 (en) | 2014-04-23 | 2015-10-29 | Novartis Ag | Novel dosing and uses of ofatumumab |
| WO2016189491A1 (en) * | 2015-05-28 | 2016-12-01 | Glaxosmithkline Intellectual Property Development Limited | Novel formulation |
| CN109563161A (zh) * | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
| RS64541B1 (sr) | 2016-08-15 | 2023-09-29 | Novartis Ag | Režimi i postupci za lečenje multiple skleroze upotrebom ofatumumaba |
| JPWO2018179138A1 (ja) * | 2017-03-29 | 2020-02-06 | 持田製薬株式会社 | 抗体含有液体製剤 |
| CN110352201A (zh) | 2017-04-03 | 2019-10-18 | 免疫医疗公司 | 用于癌症疗法的抗体药物缀合物的皮下施用 |
| RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US11513046B2 (en) * | 2018-02-09 | 2022-11-29 | Championx Usa Inc. | Flowability testing systems and methods |
| CN113056482A (zh) | 2018-10-18 | 2021-06-29 | 默沙东公司 | 抗rsv抗体的制剂及其使用方法 |
| CN120842406A (zh) | 2018-10-31 | 2025-10-28 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| CN114401742B (zh) | 2019-09-11 | 2024-05-24 | 诺华股份有限公司 | 通过转换疗法治疗rms |
| AU2020347474A1 (en) | 2019-09-11 | 2022-04-07 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| CN112675126A (zh) * | 2019-10-18 | 2021-04-20 | 百奥泰生物制药股份有限公司 | 抗cd20抗体制剂及其应用 |
| BR112022019038A2 (pt) | 2020-04-09 | 2022-11-01 | Novartis Ag | Ofatumumab para tratamento de em enquanto mantém a igg sérica |
| BR112022022730A2 (pt) | 2020-05-08 | 2023-02-14 | Genmab As | Método para tratar um linfoma não hodgkin de células b em um indivíduo humano |
| JP7057954B2 (ja) * | 2020-09-03 | 2022-04-21 | 国立大学法人大阪大学 | 改善された保存安定性を有するタンパク質含有液体製剤 |
| US20240228647A1 (en) | 2021-04-14 | 2024-07-11 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
| IL310813A (en) | 2021-08-16 | 2024-04-01 | Novartis Ag | OFATUMUMAB for the treatment of multiple sclerosis in children |
| JP2025513510A (ja) * | 2022-04-20 | 2025-04-24 | アルトス バイオロジックス インク． | オクレリズマブを含む薬学的組成物とその用途 |
| CN116712390B (zh) * | 2023-08-04 | 2023-11-14 | 上海览屹医药科技有限公司 | 一种高浓度高稳定性的抗体制剂及其制备方法 |
| WO2025037335A1 (en) * | 2023-08-12 | 2025-02-20 | Dr. Reddy's Laboratories Limited | Formulations of anti-cd20 antibody |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4816401A (en) * | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| EP0999853B1 (en) * | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| CN1245216C (zh) * | 1999-10-04 | 2006-03-15 | 希龙公司 | 稳定化的含多肽的液体药物组合物 |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| RU2004127458A (ru) | 2002-02-14 | 2005-10-27 | Иммуномедикс, Инк. (Us) | Анти-cd20 антитела, их гибридные белки и способы их использования |
| SI1478394T1 (sl) * | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| EP1551875A4 (en) * | 2002-06-21 | 2006-06-28 | Biogen Idec Inc | TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF |
| KR20110017020A (ko) * | 2002-10-17 | 2011-02-18 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| AU2003299641C1 (en) * | 2002-12-16 | 2016-06-02 | Cormorant Pharmaceuticals Ab | Human monoclonal antibodies against interleukin 8 (IL-8) |
| US8084582B2 (en) * | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| LT2620450T (lt) * | 2005-03-08 | 2019-02-11 | Pfizer Products Inc. | Anti-ctla-4 antikūnų kompozicijos |
| PL1942939T5 (pl) * | 2005-09-30 | 2021-10-11 | Medimmune Limited | Kompozycja przeciwciała interleukiny-13 |
| EP2173163A4 (en) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу |
-
2008
- 2008-03-07 UA UAA201001165A patent/UA107557C2/ru unknown
- 2008-07-03 KR KR1020157019741A patent/KR101670454B1/ko active Active
- 2008-07-03 DK DK15155712.1T patent/DK2889310T3/en active
- 2008-07-03 PL PL15155712T patent/PL2889310T3/pl unknown
- 2008-07-03 CA CA2692681A patent/CA2692681C/en active Active
- 2008-07-03 JO JOP/2008/0312A patent/JO3219B1/ar active
- 2008-07-03 EP EP15155712.1A patent/EP2889310B1/en active Active
- 2008-07-03 SI SI200831738A patent/SI2170388T1/sl unknown
- 2008-07-03 EA EA201070105A patent/EA017994B1/ru not_active IP Right Cessation
- 2008-07-03 HU HUE15155712A patent/HUE038501T2/hu unknown
- 2008-07-03 KR KR1020107000148A patent/KR20100038092A/ko not_active Withdrawn
- 2008-07-03 HU HUE08781323A patent/HUE031288T2/hu unknown
- 2008-07-03 US US12/667,890 patent/US20110020328A1/en not_active Abandoned
- 2008-07-03 WO PCT/US2008/069125 patent/WO2009009407A1/en not_active Ceased
- 2008-07-03 LT LTEP08781323.4T patent/LT2170388T/lt unknown
- 2008-07-03 SI SI200831928T patent/SI2889310T1/en unknown
- 2008-07-03 EP EP08781323.4A patent/EP2170388B1/en active Active
- 2008-07-03 PT PT87813234T patent/PT2170388T/pt unknown
- 2008-07-03 CN CN200880105866.1A patent/CN101820912B/zh active Active
- 2008-07-03 TR TR2018/02928T patent/TR201802928T4/tr unknown
- 2008-07-03 NO NO15155712A patent/NO2889310T3/no unknown
- 2008-07-03 ES ES08781323.4T patent/ES2610821T3/es active Active
- 2008-07-03 PT PT151557121T patent/PT2889310T/pt unknown
- 2008-07-03 MY MYPI2010000010A patent/MY210424A/en unknown
- 2008-07-03 LT LTEP15155712.1T patent/LT2889310T/lt unknown
- 2008-07-03 MX MX2010000017A patent/MX2010000017A/es active IP Right Grant
- 2008-07-03 AU AU2008275278A patent/AU2008275278B2/en active Active
- 2008-07-03 ES ES15155712.1T patent/ES2663504T3/es active Active
- 2008-07-03 HR HRP20170033TT patent/HRP20170033T1/hr unknown
- 2008-07-03 BR BRPI0814003-0A patent/BRPI0814003B1/pt active IP Right Grant
- 2008-07-03 PL PL08781323T patent/PL2170388T3/pl unknown
- 2008-07-03 BR BR122020026978-2A patent/BR122020026978B1/pt active IP Right Grant
- 2008-07-03 NZ NZ582250A patent/NZ582250A/en unknown
- 2008-07-03 DK DK08781323.4T patent/DK2170388T3/en active
- 2008-07-03 JP JP2010516158A patent/JP5529017B2/ja active Active
- 2008-07-04 TW TW104128324A patent/TWI612060B/zh active
- 2008-07-04 PE PE2008001136A patent/PE20090738A1/es active IP Right Grant
- 2008-07-04 TW TW097125246A patent/TWI515204B/zh active
- 2008-07-04 CL CL2008001984A patent/CL2008001984A1/es unknown
- 2008-07-04 UY UY31210A patent/UY31210A1/es not_active Application Discontinuation
- 2008-07-04 AR ARP080102910A patent/AR067455A1/es unknown
-
2009
- 2009-12-21 ZA ZA2009/09107A patent/ZA200909107B/en unknown
- 2009-12-24 IL IL202950A patent/IL202950A/en active IP Right Grant
- 2009-12-30 CO CO09149371A patent/CO6270340A2/es active IP Right Grant
- 2009-12-30 MA MA32460A patent/MA31471B1/fr unknown
-
2010
- 2010-01-05 DO DO2010000001A patent/DOP2010000001A/es unknown
- 2010-02-02 CR CR11249A patent/CR11249A/es unknown
-
2015
- 2015-02-19 US US14/625,881 patent/US20150158951A1/en not_active Abandoned
-
2017
- 2017-01-12 CY CY20171100043T patent/CY1118419T1/el unknown
- 2017-08-29 AR ARP170102392A patent/AR109461A2/es not_active Application Discontinuation
-
2018
- 2018-03-14 HR HRP20180440TT patent/HRP20180440T1/hr unknown
- 2018-03-20 CY CY20181100325T patent/CY1120047T1/el unknown
-
2021
- 2021-09-13 NO NO2021036C patent/NO2021036I1/no unknown
- 2021-09-14 CY CY2021027C patent/CY2021027I1/el unknown
- 2021-09-14 FR FR21C1040C patent/FR21C1040I1/fr active Active
- 2021-09-15 HU HUS2100038C patent/HUS2100038I1/hu unknown
- 2021-09-15 LT LTPA2021520C patent/LTPA2021520I1/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109461A2 (es) | Formulación de anticuerpo anti-cd20 y su uso para preparar un medicamento | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| CL2008003788A1 (es) | Composicion farmaceutico que comprende a) el anticuerpo b-ly1 humanizado (anti-cd20/antigeno de referenciacion restringida del linfocito b humano/bp35, de tipo ii), b) opcionalmente de 0,001% al 1%p/v de por lo menos un surfactante, y c) de 1 a 100 mm de un tampon; uso para tratar enfermedades relacionadas con cd20. | |
| AR115939A2 (es) | Composición que contiene palmitoil-etanolamida ultra-micronizada | |
| AR079556A1 (es) | Formacion de anticuerpos | |
| PE20170948A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
| MA33023B1 (fr) | Formulation d'anticorps | |
| CY1125697T1 (el) | Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων | |
| CL2011000711A1 (es) | Anticuerpo monoclonal que se une al receptor de regulacion negativa (nrr) de notch2; formulacion farmaceutica que lo comprende; y su uso para tratar una enfermedad maligna por celula b o melanoma. | |
| PE20120359A1 (es) | Formulacion con anticuerpo | |
| CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
| CR8932A (es) | Composicion de anticuerpo her2 | |
| MY157661A (en) | Bendamustine pharmaceutical compositions | |
| MA33405B1 (fr) | Anticorps anti-axl | |
| CL2016002624A1 (es) | Anticuerpos humanos que se unen al gen 3 de activación linfocitaria (lag-3) y los usos de estos (divisional sol. n°0308-2011) | |
| CL2008003537A1 (es) | Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alergica, inmunologica o inflamatoria o dolor. | |
| ECSP088962A (es) | Nuevos herbicidas | |
| CR10295A (es) | "formulacion de un anticuerpo monoclonal humano anti-igf-1r" | |
| CR20110091A (es) | Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos | |
| SV2006002143A (es) | Uso de un anticuerpo para el tratamiento del cancer resistente al platino | |
| BR112014031837A2 (pt) | formulações de progesterona | |
| AR053651A1 (es) | Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama | |
| CR10561A (es) | Vacunas para malaria | |
| CL2012001349A1 (es) | Uso de una composicion farmaceutica que comprende telmisartan para el tratamiento de hipertension sistemica en gatos ( div. sol. 2897-07). | |
| PA8809601A1 (es) | Combinación anti-retroviral |